{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:22:52Z","timestamp":1785410572586,"version":"3.56.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000038","name":"US Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.yebeh.2020.106936","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T17:27:03Z","timestamp":1582306023000},"page":"106936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy"],"prefix":"10.1016","volume":"105","author":[{"given":"Sharmila","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia Y.","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.yebeh.2020.106936_bb0005","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/epi.14439","article-title":"Generic antiepileptic drugs\u2014safe or harmful in patients with epilepsy?","volume":"59","author":"Holtkamp","year":"2018","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2020.106936_bb0010","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1528-1167.2010.02573.x","article-title":"Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability","volume":"51","author":"Bialer","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106936_bb0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eplepsyres.2017.06.007","article-title":"Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS)","volume":"135","author":"Rahman","year":"2017","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.yebeh.2020.106936_bb0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yebeh.2012.10.032","article-title":"Generic substitution in the treatment of epilepsy: patient attitudes and perceptions","volume":"26","author":"Ngo","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.106936_bb0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1528-1167.2007.01007.x","article-title":"Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes","volume":"48","author":"Andermann","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2020.106936_bb0030","author":"Food and Drug Administration"},{"key":"10.1016\/j.yebeh.2020.106936_bb0035","author":"Food and Drug Administration"},{"key":"10.1016\/j.yebeh.2020.106936_bb0040","author":"Food and Drug Administration"},{"issue":"3","key":"10.1016\/j.yebeh.2020.106936_bb0045","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/cpt.28","article-title":"Novel bioequivalence approach for narrow therapeutic index drugs","volume":"97","author":"Yu","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.yebeh.2020.106936_bb0050","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/epi.13095","article-title":"Generic lamotrigine versus brand-name LAMICTAL bioequivalence in epilepsy patients: a field test of the FDA bioequivalence standard","volume":"56","author":"Ting","year":"2015","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2020.106936_bb0055","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1474-4422(16)00014-4","article-title":"Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial","volume":"15","author":"Privitera","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2020.106936_bb0060","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5698\/1535-7511-16.3.209","article-title":"AES position statement on generic substitution of antiepileptic drugs","volume":"16","author":"Vossler","year":"2016","journal-title":"Epilepsy Currents"},{"key":"10.1016\/j.yebeh.2020.106936_bb0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.yebeh.2018.11.039","article-title":"Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy","volume":"90","author":"Das","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.106936_bb0070","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.yebeh.2016.10.036","article-title":"Subjective seizure counts by epilepsy clinical drug trial participants are not reliable","volume":"67","author":"Blachut","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.106936_bb0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.seizure.2019.02.007","article-title":"Seizure detection devices for use in antiseizure medication clinical trials: a systematic review","volume":"66","author":"Kurada","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2020.106936_bb0080","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.yebeh.2018.06.018","article-title":"Caring electronically for young outpatients who have epilepsy","volume":"87","author":"Oppenheimer","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.106936_bb0085","series-title":"Handbook of biological statistics","author":"McDonald","year":"2014"},{"key":"10.1016\/j.yebeh.2020.106936_bb0090","series-title":"Handbook of biological statistics","author":"JH","year":"2014"},{"key":"10.1016\/j.yebeh.2020.106936_bb0095","series-title":"Applied logistic regression","author":"Hosmer","year":"2000"},{"key":"10.1016\/j.yebeh.2020.106936_bb0100","series-title":"Multiple regression with discrete dependent variables","author":"Orme","year":"2009"},{"issue":"4","key":"10.1016\/j.yebeh.2020.106936_bb0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/milmed\/163.4.193","article-title":"A generic drug primer: regulatory aspects and scientific concepts","volume":"163","author":"Henderson","year":"1998","journal-title":"Mil Med"},{"key":"10.1016\/j.yebeh.2020.106936_bb0110","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-018-4791-1","article-title":"A survey of patients' perceptions of pill appearance and responses to changes in appearance for four chronic disease medications","author":"Sarpatwari","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"6","key":"10.1016\/j.yebeh.2020.106936_bb0115","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/ana.25353","article-title":"Switching the manufacturer of antiepileptic drugs is associated with higher risk of seizures: a nationwide study of prescription data in Germany","volume":"84","author":"Lang","year":"2018","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.yebeh.2020.106936_bb0120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.7326\/M13-2381","article-title":"Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case\u2013control studies","volume":"161","author":"Kesselheim","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.yebeh.2020.106936_bb0125","unstructured":"Orange Book: Approved drug products with therapeutic equivalence evaluations [internet]. Silver Spring, Maryland: U.S. Food and Drug Administration. [cited 2019 Feb 07]. Available from: https:\/\/www.accessdata.fda.gov\/scripts\/Cder\/ob\/index.cfm?resetfields=1"},{"key":"10.1016\/j.yebeh.2020.106936_bb0130","series-title":"Lexi-lamotrigine (Lexi-Drugs) online [Internet]","year":"1978"},{"key":"10.1016\/j.yebeh.2020.106936_bb0135","series-title":"Lexi-levetiracetam (Lexi-drugs) online [Internet]","year":"1978"},{"key":"10.1016\/j.yebeh.2020.106936_bb0140","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.yebeh.2017.05.010","article-title":"Association between switching antiepileptic drug products and healthcare utilization: a systematic review","volume":"73","author":"Kwan","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2020.106936_bb0145","series-title":"Vimpat: DRUGDEX system [Internet]","year":"1974"},{"key":"10.1016\/j.yebeh.2020.106936_bb0150","series-title":"Vimpat\u00ae (lacosamide) film-coated tablet, injection, and oral solution [package insert]","author":"UCB Inc","year":"2018"},{"key":"10.1016\/j.yebeh.2020.106936_bb0155","series-title":"Gabapentin: DRUGDEX system [Internet]","year":"1974"},{"key":"10.1016\/j.yebeh.2020.106936_bb0160","series-title":"Neurontin\u00ae (gabapentin) capsules, tablets, and oral solution [package insert]","author":"Parke-Davis Division of Pfizer Inc","year":"2017"},{"key":"10.1016\/j.yebeh.2020.106936_bb0165","series-title":"Lyrica: DRUGDEX system [Internet]","year":"1974"},{"key":"10.1016\/j.yebeh.2020.106936_bb0170","series-title":"Lyrica\u00ae (pregabalin) capsule and solution [package insert]","author":"Parke-Davis Division of Pfizer Inc","year":"2018"},{"key":"10.1016\/j.yebeh.2020.106936_bb0175","series-title":"Carbamazepine: DRUGDEX system [Internet]","year":"1974"},{"key":"10.1016\/j.yebeh.2020.106936_bb0180","series-title":"Tegretol\u00ae (carbamazepine) chewable, IR, and XR tablets [package insert]","author":"Novartis Pharmaceuticals Corporation","year":"2018"},{"key":"10.1016\/j.yebeh.2020.106936_bb0185","series-title":"Phenytoin: DRUGDEX system [Internet]","year":"1974"},{"key":"10.1016\/j.yebeh.2020.106936_bb0190","series-title":"Dilantin\u00ae (phenytoin) extended capsule [package insert]","author":"Parke-Davis Division of Pfizer Inc","year":"2018"},{"key":"10.1016\/j.yebeh.2020.106936_bb0195","series-title":"Phenobarbital: DRUGDEX system [Internet]","year":"1974"},{"key":"10.1016\/j.yebeh.2020.106936_bb0200","series-title":"Phenobarbital sodium injection USP\u00ae [package insert]","author":"Sandoz Canada Inc","year":"2015"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2020.106936_bb0205","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.yebeh.2015.08.014","article-title":"Comparative effectiveness of generic versus brand-name antiepileptic medications","volume":"52","author":"Gagne","year":"2015","journal-title":"Epilepsy Behav"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019311680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019311680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:32:17Z","timestamp":1761503537000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019311680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":41,"alternative-id":["S1525505019311680"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.106936","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relationship of antiepileptic drugs to generic brittleness in patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2020.106936","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106936"}}